Pfizer has agreed to develop, manufacture and commercialize Coley Pharmaceutical Group's drug ProMune. Coley Pharmaceutical Group, a privately held company that develops TLR Therapeutics, has been evaluating ProMune in clinical studies since 1998. Pfizer and Coley believe ProMune "has the potential to control and prevent lung cancer." Read more...